Combinations of targeted therapy and immunotherapy are ongoing in BRAF-mutant melanoma and currently involve the combination of BRAF inhibitors and ipilimumab, a monoclonal antibody targeting the cytotoxic T lymphocyte antigen-4 inhibitory receptor. This evidence concerns the gene BRAF and melanoma.